Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 7 Next >
Cybin to Host Virtual R&D Day on February 28, 2023
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Highlights 2022 Accomplishments and Milestones
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Provides Progress Update on its CYB004-E Phase 1 Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin’s EMBARK Program Announces Graduation of Facilitators
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin & The Chopra Foundation Recognize World Mental Health Day
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Provides Update on its Intellectual Property Portfolio
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in Upcoming Scientific and Investor Conferences
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Achieves Research and Development Milestones Ahead of Projected Timelines
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Final Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Results of Shareholders’ Meeting
From Cybin Inc.
Via Business Wire
Tickers CYBN
CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Date of Annual Meeting of Shareholders
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.